US FDA grants tentative approval to Liquidia's inhaled blood pressure drug (updated)

Liquidia

19/08/2024 11:24

(Adds shares in paragraph 1, details in paragraph 2 and 3)
       Aug 19 (Reuters) - The U.S. Food and Drug Administration
on Monday granted a tentative approval to Liquidia Corp's
 LQDA.O  drug for patients with a type of lung disorder, but
stopped short of a traditional approval, sending its shares down
nearly 22% before the bell.
    The company said it has to wait for the expiration of
regulatory exclusivity of United Therapeutics'  UTHR.O  Tyvaso
on May 23, 2025 before final approval can be granted.
    The company said it will challenge the FDA's decision to
grant regulatory exclusivity to United's Tyvaso.  
    

 (Reporting by Sneha S K and Sriparna Roy in Bengaluru; Editing
by Tasim Zahid and Shinjini Ganguli)
 ((Sneha.SK@thomsonreuters.com;))